Furthermore, prospective studies will be required to evaluate whether AML patients with high pre-HSCT BAALC/ABL1 copy numbers might benefit from additional treatment or intensification of the conditioning regimen prior to allogeneic HSCT. The gene discussed is ABL1; the disease is acute myeloid leukemia.